for the BaSICS investigators and the BRICNet members IMPORTANCE Slower intravenous fluid infusion rates could reduce the formation of tissue edema and organ dysfunction in critically ill patients; however, there are no data to support different infusion rates during fluid challenges for important outcomes such as mortality.OBJECTIVE To determine the effect of a slower infusion rate vs control infusion rate on 90-day survival in patients in the intensive care unit (ICU). DESIGN, SETTING, AND PARTICIPANTS Unblinded randomized factorial clinical trial in 75 ICUs in Brazil, involving 11 052 patients requiring at least 1 fluid challenge and with 1 risk factor for worse outcomes were randomized from May 29, 2017, to March 2, 2020. Follow-up was concluded on October 29, 2020. Patients were randomized to 2 different infusion rates (reported in this article) and 2 different fluid types (balanced fluids or saline, reported separately).INTERVENTIONS Patients were randomized to receive fluid challenges at 2 different infusion rates; 5538 to the slower rate (333 mL/h) and 5514 to the control group (999 mL/h). Patients were also randomized to receive balanced solution or 0.9% saline using a factorial design. MAIN OUTCOMES AND MEASURESThe primary end point was 90-day survival.RESULTS Of all randomized patients, 10 520 (95.2%) were analyzed (mean age, 61.1 years [SD, 17.0 years]; 44.2% were women) after excluding duplicates and consent withdrawals. Patients assigned to the slower rate received a mean of 1162 mL on the first day vs 1252 mL for the control group. By day 90, 1406 of 5276 patients (26.6%) in the slower rate group had died vs 1414 of 5244 (27.0%) in the control group (adjusted hazard ratio, 1.03; 95% CI, 0.96-1.11; P = .46). There was no significant interaction between fluid type and infusion rate (P = .98).CONCLUSIONS AND RELEVANCE Among patients in the intensive care unit requiring fluid challenges, infusing at a slower rate compared with a faster rate did not reduce 90-day mortality. These findings do not support the use of a slower infusion rate.
OBJETIVO: Descrever um modelo experimental de vasectomia laparoscópica em ratos. MÉTODOS: Foram utilizados 35 ratos Rattus norvegicus albinus da linhagem Wistar. Após a anestesia, os ratos foram submetidos ao pneumoperitôneo através da agulha de Veress com PCO2 de 7mmHg. Depois, foram transpassados pela parede abdominal um trocater de 11mm de espessura e dois trocateres com 5 mm de espessura. Através destes foram introduzidos na cavidade abdominal à ótica (10mm) e as pinças utilizadas na dissecção, cauterização e secção do canal deferente e seus vasos. RESULTADOS: Durante o ato operatório dois animais (5,74%) apresentaram sangramento, contido com cauterização. Ocorreu um óbito na indução anestésica (2,85%) e outro (2,85%) no quarto dia pós-operatório de causa não identificada. Após 08 dias havia 33 ratos vivos (94,28%). CONCLUSÃO: Neste modelo, o material cirúrgico é o mesmo utilizado em humanos e são aplicados todos os procedimentos básicos da cirurgia laparoscópica, tornando-o factível para o treinamento de acadêmicos, médicos residentes e cirurgiões.
Objective To describe the IMPACTO-MR, a Brazilian nationwide intensive care unit platform study focused on the impact of health care-associated infections due to multidrug-resistant bacteria. Methods We described the IMPACTO-MR platform, its development, criteria for intensive care unit selection, characterization of core data collection, objectives, and future research projects to be held within the platform. Results The core data were collected using the Epimed Monitor System® and consisted of demographic data, comorbidity data, functional status, clinical scores, admission diagnosis and secondary diagnoses, laboratory, clinical, and microbiological data, and organ support during intensive care unit stay, among others. From October 2019 to December 2020, 33,983 patients from 51 intensive care units were included in the core database. Conclusion The IMPACTO-MR platform is a nationwide Brazilian intensive care unit clinical database focused on researching the impact of health care-associated infections due to multidrug-resistant bacteria. This platform provides data for individual intensive care unit development and research and multicenter observational and prospective trials.
OBJETIVO: Desenvolver um modelo de esplenectomia laparoscópica em ratos. MÉTODOS: Foram utilizados trinta e cinco ratos machos ( Rattus Norvegicus Albinus, linhagem Wistar),pesando 250 +/- 50 g .Os animais foram anestesiados com cetamina e xylazina e foi estabelecido pneumoperitônio de CO2 com pressão de 7 mmHg, através da agulha de Veress. Após pneumoperitônio, dois trocateres de 5 mm e um de 11mm foram alocados na parade abdominal obedecendo a triangulação. O ligamento gastroesplênico foi dissecado para mobilização do baço. Os vasos hilares foram dissecados e eletrocoagulados utilizando a pinça "Maryland" e o gancho "HooK". Um "endobag" adaptado, foi utilizado para retirar o orgão da cavidade abdominal. RESULTADOS: Um animal (2,86%) morreu na indução anestésica. Após um período de observação de oito dias, trinta animais sobreviveram (85,7 %) e quatro (11,42%) Morreram no pós-operatório imediato. Em relação às complicações, Aderências intra-abdominais foram encontradas em 25,71% dos animais (n=9). CONCLUSÃO: A esplenectomia laparoscópica é um modelo factível por conta da baixa taxa de mortalidade além do baixo custo para treinamento da técnica.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.